Veledimex racemate NEW
| Price | $1970 | $2580 | $3400 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-27 |
Product Details
| Product Name: Veledimex racemate | CAS No.: 755013-59-3 |
| Supply Ability: 10g | Release date: 2025/10/27 |
Product Introduction
Bioactivity
| Name | Veledimex racemate |
| Description | Veledimex racemate, the racemic form of veledimex, is an orally available, small-molecule ligand that activates the RheoSwitch Therapeutic System. |
| In vitro | Interleukin 12 (IL-12) is a pro-inflammatory cytokine essential for stimulating anti-cancer immune responses. Ad-RTS-IL-12 is an adenovirus vector designed to express hIL-12. Veledimex, an orally active small molecule diacylhydrazine, controls the expression of target genes, with gene product levels and duration of action dependent on veledimex dose and administration timing. |
| In vivo | In murine models of melanoma, breast cancer, and glioma, the combined intratumoral injection of Ad-RTS-mIL-12 and oral dose of veledimex has shown to produce a dose-dependent antitumor effect. This response is associated with increased veledimex levels in plasma and tumor tissues. Notably, this combination therapy leads to a dose-responsive activation of IL-12 mRNA (switch on) and subsequent elevations of IL-12p70 within the tumor, while only minimally increasing its levels in the serum. Enhanced tumor levels of IL-12 are linked with an upsurge in CD8+ cytotoxic T cells and a reduction in regulatory T cells within the tumor microenvironment. Consequently, this regimen achieves dose-dependent reductions in tumor growth rates without significantly affecting body weight in both breast and melanoma syngeneic mouse models. Veledimex exhibits moderate to low oral bioavailability (-56% in mice and up to 17.4% in cynomolgus monkeys), alongside relatively low plasma clearance (1399 mL/h/kg in mice and 1170 mL/h/kg in monkeys), a high volume of distribution (20271 mL/kg in mice and 9180 mL/kg in monkeys), and prolonged terminal half-lives (-10 hours in mice and -30 hours in monkeys), following single oral or intravenous administrations. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Veledimex racemate |
| Inhibitors Related | Disulfiram | Sodium Thiocyanate | 10-Hydroxydecanoic Acid | Inosine pranobex | Ethyl palmitate | Theophylline monohydrate | Balsalazide disodium dihydrate | 1,8-Cineole | Benzbromarone | Prednisone acetate | Lornoxicam | Apilimod |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $59.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-09-18 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $2580.00/50mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-07-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY